Table 4.
Hemoglobin value, iron parameters and the risks of all-cause, cardiovascular, infection-related and cancer-related mortality among peritoneal dialysis patients.
| Events | IR | cHR | aHR | |
|---|---|---|---|---|
| Hemoglobin (g/dL)1 | ||||
| All-cause mortality | ||||
| < 10 | 407 | 50.36 | 1.20 (1.01–1.43), p = 0.038 | 1.23 (1.02–1.49), p = 0.03 |
| 10–10.9 | 182 | 39.79 | 1.0 (reference) | 1.0 (reference) |
| 11–11.9 | 77 | 48.19 | 1.30 (1.00–1.70), p = 0.05 | 0.97 (0.74–1.28), p = 0.85 |
| ≥ 12 | 28 | 57.80 | 1.51 (1.02–2.25), p = 0.042 | 0.88 (0.57–1.24), p = 0.54 |
| Cardiovascular mortality | ||||
| < 10 | 278 | 34.40 | 1.28 (1.03–1.59), p = 0.025 | 1.34 (1.06–1.69), p = 0.013 |
| 10–10.9 | 118 | 25.80 | 1.0 (reference) | 1.0 (reference) |
| 11–11.9 | 38 | 23.78 | 0.98 (0.68–1.42), p = 0.93 | 0.70 (0.48–1.03), p = 0.07 |
| ≥ 12 | 23 | 47.48 | 1.92 (1.23–3.01), p = 0.001 | 1.10 (0.68–1.78), p = 0.71 |
| Infection-related mortality | ||||
| < 10 | 28 | 3.46 | 0.82 (0.45–1.48), p = 0.51 | 0.69 (0.36–1.33), p = 0.27 |
| 10–10.9 | 18 | 3.94 | 1.0 (reference) | 1.0 (reference) |
| 11–11.9 | 14 | 8.76 | 2.43 (1.21–4.89), p = 0.013 | 1.96 (0.94–4.09), p = 0.07 |
| ≥ 12 | 1 | 2.06 | 0.55 (0.07–4.14), p = 0.56 | 0.42 (0.05–3.38), p = 0.41 |
| Cancer-related mortality | ||||
| < 10 | 30 | 3.71 | 1.32 (0.67–2.58), p = 0.42 | 1.39 (0.66–2.92), p = 0.38 |
| 10–10.9 | 12 | 2.62 | 1.0 (reference) | 1.0 (reference) |
| 11–11.9 | 4 | 2.50 | 1.05 (0.34–3.27), p = 0.93 | 0.74 (0.23–2.44), p = 0.62 |
| ≥ 12 | – | – | – | – |
| Ferritin (ng/mL)2 | ||||
| All-cause mortality | ||||
| < 300 | 233 | 36.63 | 1.00 (0.81–1.22), p = 0.97 | 0.94 (0.76–1.16), p = 0.56 |
| 300–499 | 148 | 37.55 | 1.0 (reference) | 1.0 (reference) |
| 500–799 | 154 | 56.84 | 1.52 (1.21–1.90), p = 0.001 | 1.08 (0.85–1.37), p = 0.51 |
| ≥ 800 | 159 | 92.06 | 2.50 (2.00–3.13), p = 0.001 | 1.31 (1.02–1.70), p = 0.036 |
| Cardiovascular mortality | ||||
| < 300 | 158 | 24.84 | 1.03 (0.80–1.33), p = 0.80 | 1.01 (0.77–1.31), p = 0.95 |
| 300–499 | 97 | 24.61 | 1.0 (reference) | 1.0 (reference) |
| 500–799 | 105 | 38.76 | 1.58 (1.20–2.09), p = 0.001 | 1.11 (0.83–1.48), p = 0.49 |
| ≥ 800 | 97 | 56.16 | 2.33 (1.76–3.08), p = 0.001 | 1.16 (0.84–1.59), p = 0.37 |
| Infection-related mortality | ||||
| < 300 | 17 | 2.67 | 0.67 (0.34–1.33), p = 0.25 | 0.56 (0.27–1.17), p = 0.12 |
| 300–499 | 16 | 4.06 | 1.0 (reference) | 1.0 (reference) |
| 500–799 | 13 | 4.80 | 1.18 (0.57–2.45), p = 0.66 | 0.98 (0.45–2.13), p = 0.96 |
| ≥ 800 | 15 | 8.69 | 2.19 (1.08–4.43), p = 0.029 | 1.41 (0.59–3.34), p = 0.44 |
| Cancer-related mortality | ||||
| < 300 | 12 | 1.89 | 0.76 (0.33–1.75), p = 0.52 | 0.71 (0.30–1.70), p = 0.44 |
| 300–499 | 10 | 2.54 | 1.0 (reference) | 1.0 (reference) |
| 500–799 | 7 | 2.58 | 1.01 (0.39–2.66), p = 0.98 | 0.60 (0.22–1.68), p = 0.33 |
| ≥ 800 | 17 | 9.84 | 3.98 (1.82–8.69), p = 0.001 | 1.78 (0.71–4.51), p = 0.22 |
| TSAT (%)3 | ||||
| All-cause mortality | ||||
| < 20 | 82 | 61.69 | 1.46 (1.14–1.86), p = 0.003 | 1.35 (1.02–1.78), p = 0.035 |
| 20–29 | 263 | 40.07 | 0.90 (0.76–1.06), p = 0.21 | 1.01 (0.84–1.22), p = 0.90 |
| 30–49 | 277 | 44.49 | 1.0 (reference) | 1.0 (reference) |
| ≥ 50 | 72 | 116.27 | 2.72 (2.10–3.53), p = 0.001 | 1.60 (1.21–2.11), p = 0.001 |
| Cardiovascular mortality | ||||
| < 20 | 54 | 40.63 | 1.45 (1.07–1.96), p = 0.017 | 1.25 (0.89–1.77), p = 0.20 |
| 20–29 | 181 | 27.58 | 0.93 (0.76–1.15), p = 0.51 | 0.99 (0.79–1.24), p = 0.95 |
| 30–49 | 184 | 29.55 | 1.0 (reference) | 1.0 (reference) |
| ≥ 50 | 38 | 61.36 | 2.18 (1.54–3.09), p = 0.001 | 1.25 (0.86–1.81), p = 0.25 |
| Infection-related mortality | ||||
| < 20 | 7 | 5.27 | 1.66 (0.70–3.90), p = 0.25 | 2.11 (0.78–5.73), p = 0.14 |
| 20–29 | 24 | 3.66 | 1.08 (0.60–1.94), p = 0.80 | 1.56 (0.81–2.99), p = 0.18 |
| 30–49 | 21 | 3.37 | 1.0 (reference) | 1.0 (reference) |
| ≥ 50 | 9 | 14.53 | 4.52 (2.07–9.88), p = 0.001 | 2.83 (1.16–6.87), p = 0.022 |
| Cancer-related mortality | ||||
| < 20 | 4 | 3.01 | 1.34 (0.44–4.03), p = 0.60 | 1.18 (0.34–4.11), p = 0.80 |
| 20–29 | 15 | 2.29 | 0.94 (0.46–1.93), p = 0.88 | 1.13 (0.52–2.48), p = 0.76 |
| 30–49 | 15 | 2.41 | 1.0 (reference) | 1.0 (reference) |
| ≥ 50 | 12 | 19.38 | 8.31 (3.88–17.8), p = 0.001 | 4.15 (1.77–9.75), p = 0.01 |
aHR: adjusted hazard ratio; cHR: crude hazard ratio; IR: incidence rate per 1000 patient-years.
1aHRs were adjusted for age, sex, diabetes, hypertension, dialysis adequacy [weekly Kt/V, and weekly creatinine clearance (weekly CCr)], estimated glomerular filtration rate (eGFR) at the start of dialysis (MDRD), white blood cell counts, the normalized protein catabolic rate (nPCR), serum albumin, cholesterol, triglyceride, ferritin, transferrin saturation, calcium, phosphate, alkaline phosphatase, intact-PTH, uric acid, erythropoiesis-stimulating agents dose, and intravenous iron use.
2aHRs were adjusted for age, sex, diabetes, hypertension, dialysis adequacy (weekly Kt/V and weekly CCr), estimated glomerular filtration rate (eGFR) at the start of dialysis (MDRD), white blood cell counts, the normalized protein catabolic rate (nPCR), serum albumin, cholesterol, triglyceride, hemoglobin, transferrin saturation, calcium, phosphate, alkaline phosphatase, intact-PTH, uric acid, erythropoiesis-stimulating agents dose, and intravenous iron use.
3aHRs were adjusted for age, sex, diabetes, hypertension, dialysis adequacy (weekly Kt/V and weekly CCr), estimated glomerular filtration rate (eGFR) at the start of dialysis (MDRD), white blood cell counts, the normalized protein catabolic rate (nPCR), serum albumin, cholesterol, triglyceride, ferritin, hemoglobin, calcium, phosphate, alkaline phosphatase, intact-PTH, uric acid, erythropoiesis-stimulating agents dose, and intravenous iron use.